The IPO’s Draft Guidelines for Pharmaceutical Patents (2026) face criticism for misquoting statutes and misinterpreting Indian patent law. Experts call for urgent revision to prevent disruption.
Critical Flaws Found in IPO’s Draft Pharmaceutical Patent Guidelines
The Intellectual Property Office’s (IPO) Draft Guidelines for Examination of Patent Applications in the Field of Pharmaceuticals, 2026, have come under sharp legal scrutiny for misquoting statutory provisions and misinterpreting key aspects of Indian patent law.
Commentators have identified errors in the draft's treatment of Sections 3(d), 3(e), and 5 of the Patents Act, 1970, particularly concerning the definition of 'enhanced efficacy' and the standard for patentability of derivatives. The guidelines allegedly impose a higher evidentiary burden than mandated by statute or judicial precedent, potentially undermining innovation in pharmaceutical R&D.
"These guidelines, if adopted as drafted, could disincentivize filings and create uncertainty in prosecution,"
Stakeholders have urged the IPO to undertake comprehensive revisions, aligning the draft with settled jurisprudence such as Novartis v. Union of India and Bayer Corporation v. Union of India. The controversy underscores the importance of transparent, legally sound policy drafting in sensitive sectors. For practitioners, the draft’s current form poses risks in prosecution strategy and client counseling, particularly for life sciences clients. The IPO is expected to invite further stakeholder inputs before finalizing the guidelines.
Citations
- Patents Act, 1970, Sections 3(d), 3(e), 5
